Exscientia Plc ADR (NASDAQ: EXAI) stock jumped 2.18% on Friday to $6.10 against a previous-day closing price of $5.97. With 0.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.62 million shares. The 52-week range on EXAI shows that it touched its highest point at $11.52 and its lowest point at $4.09 during that stretch. It currently has a 1-year price target of $9.50. Beta for the stock currently stands at 0.70.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EXAI was up-trending over the past week, with a rise of 15.97%, but this was up by 17.76% over a month. Three-month performance dropped to -6.30% while six-month performance rose 0.99%. The stock lost -12.36% in the past year, while it has gained 14.45% so far this year. A look at the trailing 12-month EPS for EXAI yields -1.43 with Next year EPS estimates of -1.39. For the next quarter, that number is -0.34. This implies an EPS growth rate of -18.43% for this year and -0.32% for next year.
Float and Shares Shorts:
At present, 122.96 million EXAI shares are outstanding with a float of 117.51 million shares on hand for trading. On Oct 30, 2023, short shares totaled 3.36 million, which was 2.70% higher than short shares on Sep 28, 2023. In addition to Prof. Andrew L. Hopkins DPHIL, FMEDSCI, FRSE FRSC as the firm’s Founder, CEO & Executive Director, Mr. Ben R. Taylor serves as its CFO, Chief Strategy Officer & Executive Director.
Institutional Ownership:
Through their ownership of 28.57% of EXAI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.39% of EXAI, in contrast to 18.48% held by mutual funds. As the largest shareholder in EXAI with 4.58% of the stake, Laurion Capital Management LP holds 5,627,444 shares worth 5,627,444. A second-largest stockholder of EXAI, Baillie Gifford & Co., holds 4,868,810 shares, controlling over 3.96% of the firm’s shares. Platinum Investment Management Lt is the third largest shareholder in EXAI, holding 4,395,058 shares or 3.57% stake. With a 0.72% stake in EXAI, the Pictet – Biotech is the largest stakeholder. A total of 884,056 shares are owned by the mutual fund manager. The iShares Biotechnology ETF, which owns about 0.47% of EXAI stock, is the second-largest Mutual Fund holder. It holds 573,690 shares valued at 3.1 million. St. James’s Place Unit Trust – UK holds 0.39% of the stake in EXAI, owning 478,134 shares worth 2.58 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EXAI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With EXAI analysts setting a high price target of $11.00 and a low target of $7.00, the average target price over the next 12 months is $9.50. Based on these targets, EXAI could surge 80.33% to reach the target high and rise by 14.75% to reach the target low. Reaching the average price target will result in a growth of 55.74% from current levels.
